Focal Biosciences is a spin-off from ETH Zurich developing a high-throughput drug discovery platform to reverse fibrotic diseases by targeting chromatin remodeling with small molecules. Our approach in IPF is focused on reprogramming lung myofibroblasts within tissue-mimicking disease models back to a normal fibroblast state, enabled by machine learning-derived chromatin fingerprints from single-cell imaging data.